1,638
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Ototoxicity monitoring through the eyes of the treating physician: Perspectives from pulmonology and medical oncology

ORCID Icon, , , , &
Pages S42-S47 | Received 14 Feb 2017, Accepted 14 Sep 2017, Published online: 05 Oct 2017

References

  • American Academy of Audiology (AAA). 2009. “Position Statement and Clinical Practice Guidelines: Ototoxicity Monitoring.” https://audiology-web.s3.amazonaws.com/migrated/OtoMonGuidelines.pdf_539974c40999c1.58842217.pdf
  • American Speech Language Hearing Association (ASHA). 1994. “Guidelines for the Audiologic Management of Individuals Receiving Cochleotoxic Drug Therapy.” ASHA 36 (Suppl 12): 11–19.
  • Chen, X., Y. Wu, H. Dong, C. Y. Zhang, and Y. Zhang. 2013. “Platinum-Based Agents for Individualized Cancer Treatment.” Current Molecular Medicine 13: 1603–1612.
  • Damschroder, L. J., D. C. Aron, R. E. Keith, S. R. Kirsh, J. A. Alexander, and J. C. Lowery. 2009. “Fostering Implementation of Health Services Research Findings into Practice: A Consolidated Framework for Advancing Implementation Science.” Implementation Science 4:50. doi:10.1186/1748-5908-4-50
  • Drobnic, M. E., P. Sune, J. B. Montoro, A. Ferrer, and R. Orriols. 2005. “Inhaled Tobramycin in Non-Cystic Fibrosis Patients with Bronchiectasis and Chronic Bronchial Infection with Pseudomonas aeruginosa.” Annals of Pharmacotherapy 39: 39–44. doi:10.1345/aph.1E099
  • Egelund, E. F., K. P. Fennelly, and C. A. Peloquin. 2015. “Medications and Monitoring in Nontuberculous Mycobacteria Infections.” Clinics in Chest Medicine 36: 55–66.
  • Garinis, A. C., C. P. Cross, P. Srikanth, K. Carroll, M. P. Feeney, D. H. Keefe, L. L. Hunter, et al. 2017. “The Cumulative Effects of Intravenous Antibiotic Treatments on Hearing in Patients with Cystic Fibrosis.” J Cys Fib 16: 401–409.
  • Konrad-Martin, D., G. L. Poling, A. C. Garnins, C. Ortiz, J. Hopper, K. O'Connell-Bennett, and M. F. Dille. 2017. “Applying U.S. National Guidelines for Ototoxicity Monitoring in Adult Patients: Perspectives on Patient Populations, Service Gaps, Barriers and Solutions.” International Journal of Audiology. Accepted.
  • Moore, R. D., C. R. Smith, and P. S. Lietman. 1984. “Risk Factors for the Development of Auditory Toxicity in Patients Receiving Aminoglycosides.” The Journal of infectious diseases 149: 23–30.
  • Nordstrom, L., and S. A. Lerner.1991. “Single Daily Dose Therapy with Aminoglycosides.” The Journal of Hospital Infection 18 (Suppl A): 117–129.
  • Orriols, R., J. Roig, J. Ferrer, G. Sampol, A. Rosell, A. Ferrer, A. Vallano, et al. 1999. “Inhaled Antibiotic Therapy in Non-Cystic Fibrosis Patients with Bronchiectasis and Chronic Bronchial Infection by Pseudomonas aeruginosa.”RespMed 93: 476–480.
  • Patatanian, L. 2006. “Inhaled Tobramycin-Associated Hearing Loss in an Adolescent with Renal Failure.” The Pediatric infectious disease journal 25: 276–278. doi:10.1097/01.inf.0000202126.44544.41
  • Prescott, W. A. Jr. 2014. “A Survey of Extended-Interval Aminoglycoside Dosing Practices in United States Adult Cystic Fibrosis Programs.” Respir Care 59: 1353–1359.
  • Schacht, J. 2007. “Aminoglycoside antibiotics." In Pharmacology and Ototoxicity for Audiologists, edited by K. Campbell, 163–176. Clifton Park, NY: Thomson Delmar Learning.
  • Shamseddine, A. I., and F. S. Farhat. 2011. “Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer.” Chemotherapy 57: 468–487. doi:10.1159/000334093
  • Strojan, P., J. B. Vermorken, J. J. Beitler, N. F. Saba, M. Haigentz, P. Bossi, F. P. Worden, et al. 2016. “Cumulative Cisplatin Dose in Concurrent Chemoradiotherapy for Head and Neck Cancer: A Systematic Review.”Head & Neck 38 (Suppl 1): E2151–E2158. doi:10.1002/hed.24026
  • Theunissen, E. A. R., S. C. J. Bosma, C. L. Zuur, R. Spijker, S. van der Baan, W. A. Dreschler, J. P. de Boer, et al. 2015. “Sensorineural Hearing Loss in Patients with Head and Neck Cancer After Chemoradiotherapy and Radiotherapy: A Systematic Review of the Literature.” Head & Neck 37: 281–292.
  • Vasquez, R., and K. F. Mattucci. 2003. “A Proposed Protocol for Monitoring Ototoxicity in Patients who take Cochleo- or Vestibulotoxic Drugs.” Ear, Nose, & Throat Journal 82: 181–184.
  • Wusthoff, C. J., A. McMillan, and A. R. Ablin. 2005. “Differences in Pediatric Oncologists' Estimates of Curability and Treatment Recommendations for Patients with Advanced Cancer.” Pediatric Blood & Cancer 44: 174–181. doi:10.1002/pbc.20153